| ZFIN ID: ZDB-EXP-260518-4 |
Experiment Conditions Description: chemical treatment by environment: methocarbamol, chemical treatment by environment: N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal
| chemical treatment by environment: methocarbamol |
|---|
| Name: | chemical treatment by environment |
|---|---|
| Synonyms: | |
| Definition: | Chemical treatment condition in which the chemical is introduced through the environment. For zebrafish this is the tank water. |
| Ontology: | Zebrafish Environment Condition Ontology [ZECO:0000238] |
| Name: | methocarbamol |
|---|---|
| Synonyms: | (+-)-2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate, (+-)-3-(o-methoxyphenoxy)-1,2-propanediol 1-carbamate, 2-hydroxy-3-(o-methoxyphenoxy)propyl 1-carbamate, 3-(2-methoxyphenoxy)-1-glyceryl carbamate, 3-(o-methoxyphenoxy)-1,2-propanediol 1-carbamate, 3-(o-methoxyphenoxy)-2-hydroxypropyl carbamate, Delaxin, glycerylguaiacolate carbamate, guaiacol glyceryl ether carbamate, methocarbamol, methocarbamolum, metocarbamol, Myolaxene, Parabaxin, rac-2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate, Reflexyn, Relestrid, Robamol, Robaxin, Robinax, Romethocarb, Tresortil |
| Definition: | A racemate comprising equimolar amounts of (R)- and (S)-methocarbamol. A centrally acting skeletal muscle relaxant, it is used as an adjunct in the short-term symptomatic treatment of painful muscle spasm. The (R)-enantiomer is more active than the (S)-enantiomer. |
| Ontology: | ChEBI [CHEBI:6832] ( EBI ) |
| chemical treatment by environment: N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal |
|---|
| Name: | chemical treatment by environment |
|---|---|
| Synonyms: | |
| Definition: | Chemical treatment condition in which the chemical is introduced through the environment. For zebrafish this is the tank water. |
| Ontology: | Zebrafish Environment Condition Ontology [ZECO:0000238] |
| Name: | N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal |
|---|---|
| Synonyms: | (S)-N-((phenylmethoxy)carbonyl)-L-leucyl-N-(1-formyl-3-methylbutyl)-L-leucinamide, benzyloxycarbonyl-leu-leu-leu-aldehyde, benzyloxycarbonyl-leucyl-leucyl-leucinal, benzyloxycarbonylleucyl-leucyl-leucine aldehyde, carbobenzoxy-Leu-Leu-leucinal, carbobenzoxy-leucyl-leucyl-leucinal, carbobenzoxyl-leucinyl-leucinyl-leucinal-H, Cbz-L-Leu-L-Leu-L-Leu-CHO, Cbz-L-Leu-L-Leu-L-Leu-H, Cbz-Leu-Leu-Leu-CHO, Cbz-Leu-Leu-Leu-H, Cbz-Leu-Leu-Leucinal, MG 132, MG-132, N-[(benzyloxy)carbonyl]-L-leucyl-N-[(2S)-4-methyl-1-oxopentan-2-yl]-L-leucinamide, Z-Leu-Leu-Leu-al, Z-Leu-Leu-Leu-CHO, Z-Leu-Leu-Leu-H, Z-Leu-Leu-Leucinal, Z-LLL-CHO, Z-LLL-H, Z-LLLal, ZLLL-CHO, ZLLLal |
| Definition: | A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative. |
| Ontology: | ChEBI [CHEBI:75142] ( EBI ) |
| Publication: | Lopez et al., 2024 |
|---|